Oct 7, 2026 07:03AM
Oct 7, 2026 07:00AM
Sep 21, 2026 04:30PM
Aug 13, 2026 04:15PM
Aug 3, 2026 08:30AM
Aug 3, 2026 08:30AM
Jul 21, 2026 08:03AM Cadrenal Therapeutics seeks partners for cardiac drug portfolio
Jul 21, 2026 08:00AM
Jul 13, 2026 09:01AM
Jul 13, 2026 09:00AM
Jun 30, 2026 08:00PM
Jun 30, 2026 08:00PM
Jun 24, 2026 08:01AM
Jun 24, 2026 08:00AM Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Jun 18, 2026 09:01AM
Jun 18, 2026 09:00AM
Jun 15, 2026 08:30AM
Jun 15, 2026 08:30AM
Jun 3, 2026 09:02AM
Jun 3, 2026 09:00AM
May 19, 2026 04:30PM Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 7, 2026 08:30AM
May 7, 2026 08:30AM
Apr 30, 2026 08:30AM
Apr 30, 2026 08:30AM
Mar 31, 2026 08:45AM
Mar 31, 2026 08:45AM
Mar 12, 2026 08:00AM Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
Mar 2, 2026 08:01AM
Mar 2, 2026 08:00AM
Feb 24, 2026 08:30AM
Feb 24, 2026 08:30AM
Jan 12, 2026 08:02AM
Jan 12, 2026 08:00AM
Dec 11, 2025 08:05AM Cadrenal Therapeutics acquires VLX-1005 drug for blood clotting disorder
Dec 11, 2025 08:05AM
Aug 5, 2025 06:01AM
Aug 5, 2025 06:00AM
May 8, 2025 08:00AM
Mar 13, 2025 04:05PM
Jan 9, 2025 08:44AM
Dec 31, 2024 08:00AM Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
Nov 12, 2024 09:00AM
Nov 7, 2024 09:00AM
Aug 22, 2024 09:03AM
Aug 22, 2024 09:00AM
Aug 20, 2024 09:00AM
Aug 14, 2024 09:00AM
Aug 7, 2024 04:05PM Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
Aug 6, 2024 09:00AM

334,453 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All